Dihydrorotenone Inhibitor

Solid. Powder

98.00%

Store at -20 degree C for 3 years powder
-80 degree C for 2 years in solvent

396.43

<1mg/ml refers to the product slightly soluble or insoluble

C23H24O6

CC(C)[C@@H](C1)Oc(cc2)c1c(O[C@H]1[C@@H]3c(cc(c(OC)c4)OC)c4OC1)c2C3=O

6659-45-6

p53
Akt
ERK

Dihydrorotenone arrested human plasma cancer cells at the G0/G1 phase of the cell cycle. Dihydrorotenone inhibited cyclin D2 transactivation, thus inhibiting its mRNA expression. In addition, Dihydrorotenone upregulated the cell cycle repressors p21 and p53. Dihydrorotenone also increased the phosphorylation level of p53, suggesting the upregulated transactivation function of p53, which was confirmed by the induction of p21, a substrate of activated p53. Moreover, Dihydrorotenone downregulated AKT and ERK phosphorylation, an incentive of cell cycle progression.

Apoptosis; p53; Cytoskeletal Signaling; MAPK